MAP2K7 and neoplasm: Taken together, these results indicated that association of MEK and PI3K/mTOR inhibitors with TRAIL, or MEK blockade with TRAIL, leads to synergistic anti-tumor effects on most melanoma cell lines, even on inhibitor- or TRAIL-resistant ones.